Uniunea Europeană -
română -
EMA (European Medicines Agency)
teysuno
nordic group b.v. - tegafur, gimeracil, oteracil - neoplasme de stomac - agenți antineoplazici - teysuno is indicated in adults:- for the treatment of advanced gastric cancer when given in combination with cisplatin (see section 5. - as monotherapy or in combination with oxaliplatin or irinotecan, with or without bevacizumab, for the treatment of patients with metastatic colorectal cancer for whom it is not possible to continue treatment with another fluoropyrimidine due to hand-foot syndrome or cardiovascular toxicity that developed in the adjuvant or metastatic setting.
România -
română -
ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)
teysuno 15mg/4,35mg/11,8mg
nordic pharma - olanda - combinatii (tegafur+gimeracil+oteracil) - caps. - 15mg/4,35mg/11,8mg - antimetaboliti analogi ai bazelor pirimidinice
România -
română -
ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)
teysuno 20mg/5,8mg/15,8mg
nordic pharma - olanda - combinatii (tegafur+gimeracil+oteracil) - caps. - 20mg/5,8mg/15,8mg - antimetaboliti analogi ai bazelor pirimidinice